Antibiotic therapy and prophylaxis in COPD

Sapey, 2006, COPD exacerbations: aetiology, Thorax, 61, 250, 10.1136/thx.2005.041822 Groenewegen, 2003, Mortality and mortality-related factors after hospitalization for acute exacerbations of COPD, Chest, 124, 459, 10.1378/chest.124.2.459 Monso, 1995, Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush, Am J Respir Crit Care Med, 152, 1316, 10.1164/ajrccm.152.4.7551388 Soler, 1998, Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation, Am J Respir Crit Care Med, 157, 1498, 10.1164/ajrccm.157.5.9711044 Moller, 1998, Haemophilus influenzae in lung explants of patients with end-stage pulmonary disease, Am J Respir Crit Care Med, 157, 950, 10.1164/ajrccm.157.3.9707010 Bandi, 2001, Non-typeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis, Am J Respir Crit Care Med, 164, 2114, 10.1164/ajrccm.164.11.2104093 Sethi, 2002, New strains of bacteria and exacerbations of chronic obstructive pulmonary disease, N Engl J Med, 347, 465, 10.1056/NEJMoa012561 Sethi, 2004, Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 169, 448, 10.1164/rccm.200308-1181OC Sethi, 2004, Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon?, Proc Am Thorac Soc, 1, 109, 10.1513/pats.2306029 Murphy, 2005, Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response, Am J Respir Crit Care Med, 172, 195, 10.1164/rccm.200412-1747OC Murphy, 2006, The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease, Curr Opin Infect Dis, 19, 225, 10.1097/01.qco.0000224815.89363.15 Hurst, 2006, Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 173, 71, 10.1164/rccm.200505-704OC Berenson, 2005, Outer membrane protein P6 of non-typeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines, Infect Immunol, 73, 2728, 10.1128/IAI.73.5.2728-2735.2005 Chin, 2005, Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers, Am J Respir Crit Care Med, 172, 85, 10.1164/rccm.200412-1687OC White, 2003, Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis, Thorax, 58, 680, 10.1136/thorax.58.8.680 Bach, 2001, Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence, Ann Intern Med, 134, 600, 10.7326/0003-4819-134-7-200104030-00016 Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD004403. Anthonisen, 1987, Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease, Ann Intern Med, 106, 196, 10.7326/0003-4819-106-2-196 Stockley, 2000, Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD, Chest, 117, 1638, 10.1378/chest.117.6.1638 Allegra, 2005, Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease, Respir Med, 99, 742, 10.1016/j.rmed.2004.10.020 Evans, 2002, Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial, Lancet, 359, 1648, 10.1016/S0140-6736(02)08597-5 Allegra, 2001, Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study, Pulm Pharmacol Ther, 14, 149, 10.1006/pupt.2001.0289 Nouira, 2001, Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial, Lancet, 358, 2020, 10.1016/S0140-6736(01)07097-0 Woodhead, 2005, Guidelines for the management of adult lower respiratory tract infections, Eur Respir J, 26, 1138, 10.1183/09031936.05.00055705 Monso, 1999, Risk factors for lower airway bacterial colonization in chronic bronchitis, Eur Respir J, 13, 338, 10.1034/j.1399-3003.1999.13b20.x Miravitlles, 1999, Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD, Chest, 116, 40, 10.1378/chest.116.1.40 Eller, 1998, Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function, Chest, 113, 1542, 10.1378/chest.113.6.1542 Mogulkoc, 1999, Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection, Am J Respir Crit Care Med, 160, 349, 10.1164/ajrccm.160.1.9809041 Blasi, 1993, Chlamydia pneumoniae infection in acute exacerbations of COPD, Eur Respir J, 6, 19, 10.1183/09031936.93.06010019 Hoban, 2001, Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program 1997–1999, Clin Infect Dis, 32, S81, 10.1086/320181 Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN and the Alexander project Group. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired lower respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229–46. American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77–121 Doern, 2004, Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000–01, J Infect, 48, 56, 10.1016/S0163-4453(03)00123-3 Ho, 2001, Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong-Kong multicentre study in 2000, J Antimicrob Chemother, 48, 659, 10.1093/jac/48.5.659 Thornsberry, 1999, Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study, Antimicrob Agents Chemother, 43, 2612, 10.1128/AAC.43.11.2612 Schito, 2000, The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project, J Antimicrob Chemother, 46, 3, 10.1093/oxfordjournals.jac.a020891 Doern, 1999, Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997), Antimicrob Agents Chemother, 43, 385, 10.1128/AAC.43.2.385 Lonks, 2002, Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae, Clin Infect Dis, 35, 556, 10.1086/341978 Anzueto, 1997, Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group, Clin Ther, 19, 989, 10.1016/S0149-2918(97)80051-3 Dewan, 2000, Acute exacerbation of COPD: factors associated with poor treatment outcome, Chest, 117, 662, 10.1378/chest.117.3.662 Wilson, 1999, Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis, J Antimicrob Chemother, 44, 501, 10.1093/jac/44.4.501 Chodosh, 2000, Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group, Respir Med, 94, 18, 10.1053/rmed.1999.0708 DeAbate, 2000, The safety and efficacy of short course (5-day) moxifloxacin vs azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis, Respir Med, 94, 1029, 10.1053/rmed.2000.0927 Adams, 2000, Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD, Chest, 117, 1345, 10.1378/chest.117.5.1345 Cabello, 1997, Bacterial colonization of the distal airways in healthy subjects and chronic lung disease: a bronchoscopic study, Eur Respir J, 10, 1137, 10.1183/09031936.97.10051137 Soler, 1999, Airway inflammation and bronchial microbial patterns with stable chronic obstructive pulmonary disease, Eur Respir J, 14, 1015, 10.1183/09031936.99.14510159 Banerjee, 2004, Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD, Eur Respir J, 23, 685, 10.1183/09031936.04.00056804 Hurst, 2005, Relationship among bacteria, upper airway, lower airway, and systemic inflammation in COPD, Chest, 127, 1219, 10.1378/chest.127.4.1219 Wilkinson, 2003, Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 167, 1090, 10.1164/rccm.200210-1179OC Murphy, 2004, Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 170, 266, 10.1164/rccm.200403-354OC Black P, Staykova T, Chacko E, Ram FS, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. The Cochrane Library, Issue 1, 2003. Sethi, 2006, Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse’ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data, Eur Respir J, 28, 842s